ERBB2 and gastric cancer: The results showed that the CNV of ERBB2 Amp was significantly higher than ERBB2 Fusion + Amp in pan-cancer (Figure 5A), gastric cancer (Figure 5B), colorectal cancer (Figure 5C), and breast cancer (Figure 5D) (P<0.01).